Business
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally a
About this update from Purple Biotech Ltd.
[{"type":"image","alt":"Purple Biotech Ltd.","displaySize":"","headline":null,"caption":"Purple Biotech Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":250,"url":"https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/b_q3OJwHS.6FpUIZPiP7Sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5","width":300,"height":250}},"lazy":false},{"type":"text","content":"New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated tri-specific antibodies at the upcoming European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress being held from December 10–12, 2025, in London, United Kingdom. ","length":730,"tagName":"p"},{"type":"text","content":"Presentation Details: ","length":21,"tagName":"p"},{"type":"text","content":"● Conference: ESMO Immuno-Oncology (ESMO-IO) 2025 Annual Congress● Title: CAPTN-3 unique design demonstrated by 2 novel platform compounds● Presenter: Dr. Hadas Reuveni● Presentation Number: FPN# 287P● Session Title: Poster Presentation● Date/Time: Wednesday, December 10, 2025, 17:15● Location: London, UK","length":438,"tagName":"p","attribs":{}},{"type":"text","content":"“Our CAPTN-3 platform can produce novel tri-specific antibodies that engage T cells, NK cells and bind to tumor associated antigens. The powerful synergy we have seen in preclinical studies strengthens our conviction in not only the platform, but also in this novel structure to overcome tumor evasion and drug resistance. We look forward to showcasing new data from our lead CAPTN-3 program, IM1240, in multiple PD-1 resistant models, and new data demonstrating the platfo...